StockData
INBPOTCPharmaceutical PreparationsFiscal year ends June 30

INTEGRATED BIOPHARMA INC

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$0.18+0.00 (0.00%)

Close on Oct 19, 2026

Market cap
$5.59M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 9, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q4 FY2026
Ended Jun 30, 2026
Sep 25, 2026During market hours$9.80M$-0.04–
Q3 FY2026
Ended Mar 31, 2026
May 8, 2026During market hours$10.10M$-0.03–
Q2 FY2026
Ended Dec 31, 2025
Feb 11, 2026During market hours$11.30M$-0.03–
Q1 FY2026
Ended Sep 30, 2025
Nov 10, 2025During market hours$12.70M$0.00–
Q4 FY2025
Ended Jun 30, 2025
Sep 23, 2025During market hours$14.20M$-0.01–
Q3 FY2025
Ended Mar 31, 2025
May 14, 2025During market hours$13.90M$0.02–
Q2 FY2025
Ended Dec 31, 2024
Feb 13, 2025During market hours$12.60M$0.00–
Q1 FY2025
Ended Sep 30, 2024
Nov 14, 2024During market hours$13.60M$0.01–
Q4 FY2024
Ended Jun 30, 2024
Sep 23, 2024Before market open–––
Q3 FY2024
Ended Mar 31, 2024
May 10, 2024During market hours–––
Q2 FY2024
Ended Dec 31, 2023
Feb 12, 2024During market hours–––

Press releases

Announcements Integrated Biopharma filed with the SEC